Skip to main content
Midas Edge

Jasper Therapeutics, Inc.

For the period ended Dec 31, 2025. Filed Mar 30, 2026.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Mar 30, 2026

JSPR$14.75-9.9%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Item 15. Exhibit and Financial Statement Schedules

ITEM 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES

(a)(1) Financial Statements

Our Financial Statements are listed in the “Index to the Financial Statements” of Jasper Therapeutics, Inc. in Part II, Item 8 of this Annual Report on Form 10-K.

(a)(2) Financial Statement Schedules

All financial statement schedules have been omitted because they are not required, not applicable, or the required information is included in the consolidated financial statements or notes thereto included in Part II, Item 8 of this Annual Report on Form 10-K.

(a)(3) Exhibits

The following exhibits are filed herewith or incorporated herein by reference:

Incorporated by Reference
Exhibit NumberDescriptionFormFile NumberFiling DateExhibit
2.1+Business Combination Agreement, dated as of May 5, 2021, by and among Amplitude Healthcare Acquisition Corporation, Ample Merger Sub, Inc., and Jasper Therapeutics, Inc.8-K001-391385/6/20212.1
3.1Second Amended and Restated Certificate of Incorporation of the Registrant.8-K001-391389/29/20213.1
3.2Certificate of Amendment to the Second Amended and Restated Certificate of Incorporation, dated June 8, 2023.8-K001-391386/8/20233.1
3.3Certificate of Second Amendment to the Second Amended and Restated Certificate of Incorporation of Jasper Therapeutics, Inc., filed with the Secretary of State of the State of Delaware on January 3, 2024.8-K001-391381/3/20243.1
3.4Third Amended and Restated Bylaws of the Registrant.8-K001-391382/17/20233.1
4.1Form of Warrant Agreement, dated November 19, 2019, by and between the Registrant and Continental Stock Transfer & Trust Company, as warrant agent.8-K001-3913811/25/20194.1
4.2Specimen Warrant Certificate.S-1/A333-23432411/6/20194.3
4.3Form of Pre-Funded Warrant to Purchase Common Stock.8-K001-391389/19/20254.1
4.4Form of Common Warrant.8-K001-391389/19/20254.2
4.5*Description of Securities of Jasper Therapeutics, Inc.
10.1Jasper Therapeutics, Inc. 2021 Equity Incentive Plan8-K001-391389/29/202110.3
10.2Amended and Restated Registration Rights Agreement, dated September 24, 2021.8-K001-391389/29/202110.2
10.3#Jasper Therapeutics, Inc. 2024 Equity Incentive Plan.S-8333-2800396/7/20244.3
10.4#Form of Stock Option Award Agreement under the Jasper Therapeutics, Inc. 2024 Equity Incentive Plan.S-8333-2800396/7/20244.4
10.5#Form of Restricted Stock Unit Award Agreement under the Jasper Therapeutics, Inc. 2024 Equity Incentive Plan.S-8333-2800396/7/20244.5
10.6#Form of Restricted Stock Award Agreement under the Jasper Therapeutics, Inc. 2024 Equity Incentive Plan.S-8333-2800396/7/20244.6
10.7#Jasper Therapeutics, Inc. 2024 Employee Stock Purchase Plan.S-8333-2800396/7/20244.7
10.8#Jasper Therapeutics, Inc. 2022 Amended and Restated Inducement Equity Incentive Plan.8-K001-391386/8/202310.1
10.9#Jasper Therapeutics, Inc. 2022 Inducement Equity Incentive Plan Form of Stock Option Agreement and Terms and Conditions of Stock Option Grant.S-8333-2637023/18/202210.6
10.10#Jasper Therapeutics, Inc. 2022 Inducement Equity Incentive Plan Form of Restricted Stock Unit Agreement and Terms and Conditions of Restricted Stock Unit Grant.S-8333-2637023/18/202210.7
10.11#Jasper Therapeutics, Inc. 2019 Equity Incentive Plan.S-4/A333-2568757/19/202110.12
10.12#Amended and Restated Employment Agreement, dated as of June 10, 2024, by and between Jasper Therapeutics, Inc. and Ronald Martell.8-K001-391386/12/202410.3
10.13#Amended and Restated Employment Agreement, dated as of June 10, 2024, by and between Jasper Therapeutics, Inc. and Herb Cross.8-K001-391386/12/202410.4
10.14#Amended and Restated Employment Agreement, dated as of June 10, 2024, by and between Jasper Therapeutics, Inc. and Jeet Mahal.8-K001-391386/12/202410.5
10.15#Consulting Agreement, dated December 16, 2019, by and between Jasper Therapeutics, Inc. and Judith Shizuru, M.D., Ph.D.S-4/A333-2568758/9/202110.29
10.16#Jasper Therapeutics, Inc. Non-Employee Director Compensation Policy.10-K001-391382/28/202510.17
10.17#Form of Indemnification Agreement by and between Jasper Therapeutics, Inc. and each of its directors and executive officers.S-4/A333-2568757/19/202110.28
10.18^Exclusive License Agreement, dated November 21, 2019, by and between Jasper Therapeutics, Inc. and Amgen Inc.S-4/A333-2568758/9/202110.13
10.19Assignment Agreement, dated as of November 21, 2019, by and between Jasper Therapeutics, Inc. and Amgen Inc.S-4/A333-2568758/9/202110.14
10.20^Investigator Sponsored Research Agreement, Amgen Protocol No. 20119244, effective as of June 18, 2013, between Jasper Therapeutics, Inc., as successor in interest to Amgen Inc., and The Board of Trustees of the Leland Stanford Junior University for Stanford University.S-4/A333-2568758/9/202110.15
10.21^Amendment #1 to the Investigator Sponsored Research Agreement, Amgen Protocol No. 20119244, dated February 27, 2017, between Jasper Therapeutics, Inc., as successor in interest to Amgen Inc., and The Board of Trustees of the Leland Stanford Junior University for Stanford University.S-4/A333-2568758/9/202110.16
10.22^Amendment #2 to the Investigator Sponsored Research Agreement, Amgen Protocol No. 20119244, dated November 15, 2017, between Jasper Therapeutics, Inc., as successor in interest to Amgen Inc., and The Board of Trustees of the Leland Stanford Junior University for Stanford University.S-4/A333-2568758/9/202110.17
10.23^Quality Agreement, dated October 7, 2015, by and between Jasper Therapeutics, Inc., as successor in interest to Amgen Inc., and The Board of Trustees of the Leland Stanford Junior University for Stanford University.S-4/A333-2568758/9/202110.18
10.24^Exclusive License Agreement, effective as of March 25, 2021, by and between Jasper Therapeutics, Inc. and The Board of Trustees of the Leland Stanford Junior University.S-4/A333-2568758/9/202110.19
10.25^Amendment No. 1 to the Exclusive License Agreement, dated July 27, 2023, between Stanford University and Jasper Therapeutics, Inc.10-Q001-391388/11/202310.2
10.26^Sponsored Research Agreement, effective September 1, 2020, by and between Jasper Therapeutics, Inc. and The Board of Trustees of the Leland Stanford Junior University.S-4/A333-2568758/9/202110.20
10.27^Development and Manufacturing Services Agreement, dated November 29, 2019, by and between Jasper Therapeutics, Inc. and Lonza Sales AG.S-4/A333-2568758/20/202110.25
10.28^Amendment No. 1 to Development and Manufacturing Services Agreement, executed April 24, 2020 by and between Jasper Therapeutics, Inc. and Lonza Sales AG.S-4/A333-2568758/20/202110.26
10.29^Amendment No. 2 to Development and Manufacturing Services Agreement, executed December 1, 2020, by and between Jasper Therapeutics, Inc. and Lonza Sales AG.S-4/A333-2568758/20/202110.27
10.30Open Market Sale AgreementSM, dated as of March 19, 2025, by and between Jasper Therapeutics, Inc. and Jefferies LLC.S-3333-2859143/19/20251.2
19.1Jasper Therapeutics, Inc. Insider Trading Policy.10-K001-391382/28/202519.1
21.1List of Subsidiaries of the Registrant.8-K001-391389/29/202121.1
23.1*Consent of Independent Registered Public Accounting Firm.
31.1*Certification of the Principal Executive Officer pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934.
31.2*Certification of the Principal Financial Officer pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934.
32.1**Certification of the Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
97Jasper Therapeutics, Inc. Clawback Policy10-K001-391383/5/202497
101.INS*Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
101.SCH*Inline XBRL Taxonomy Extension Schema Document.
101.CAL*Inline XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF*Inline XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB*Inline XBRL Taxonomy Extension Label Linkbase Document.
101.PRE*Inline XBRL Taxonomy Extension Presentation Linkbase Document.
104*Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101).
+The annexes, schedules, and certain exhibits to the Business Combination Agreement have been omitted pursuant to Item 601(b)(2) of Regulation S-K. The Registrant hereby agrees to furnish supplementally a copy of any omitted annex, schedule or exhibit to the SEC upon request.
#Indicates a management contract or compensatory plan or arrangement.
^Certain identified information has been omitted pursuant to Item 601(b)(10) of Regulation S-K because such information is both (i) not material and (ii) of the type that the Registrant treats as private or confidential. The Registrant hereby undertakes to furnish supplemental copies of the unredacted exhibit upon request by the SEC.
*Filed herewith.
**Furnished herewith.
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.